Indoco Remedies Ltd. announces final approval from the United States Food & Drug Administration (FDA) for lacosamide tablets USP 50 mg, 100 mg, 150 mg and 200 mg, the generic version of Vimpat tablets of UCB, Inc.
Lacosamide tablets are indicated for the prevention and control of seizures. It is an anticonvulsant/antiepileptic drug.
Commenting on the development, Aditi Kare Panandikar, managing director, Indoco Remedies said,
